FDA Expands Approval of Ribociclib to Early Breast Cancer
MedPage Today) — The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breast cancer. Already approved in the metastatic setting, the CDK4/6 inhibitor is now also indicated…
MedPage Today) — The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breast cancer.
Already approved in the metastatic setting, the CDK4/6 inhibitor is now also indicated…
Read More
About Author
